GLP1R and obesity due to melanocortin 4 receptor deficiency: New generation anti-obesity medications (AOMs), particularly nutrient-stimulated hormone (NuSH)-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), show promise in addressing the obesity pandemic.